Abstract
Purpose – determine the characteristics of changes of procoagulant, anticoagulant and fibrinolytic links of the hemostatic system in patients with hypertension in combination with coronary heart disease.
 Materials and methods. 127 people were examined - 14 healthy (control), 61 patients with stage II hypertension with concomitant coronary heart disease (group 2), 52 hypertensive patients with stage III with concomitant coronary heart disease (group 3). There were evaluated indicators of hemostasis system: thrombin time, activated partial thromboplastin time, prothrombin index, soluble fibrin monomer complex, fibrinogen, protein C, antithrombin III of, and the time of XII-dependent fibrinolysis.
 Results. Patients on both study groups SFMC content significantly higher than the control group. SFMC content in patients with stage II hypertension with concomitant coronary heart disease exceed normative value of 3 times, and in the group of hypertensive patients with stage III with with concomitant coronary heart disease of 3.65 times. The content of fibrinogen in the third group of patients exceeded the indicators of the control group by 27.6%, the difference was significant (p<0,001). Also valid was the difference between the two comparable groups (p<0,001). The content of protein C in hypertensive patients stage III was lower than the control values at 28,7% (p<0,001). The difference between comparable groups also were significantly (p<0,001). At the same time, and XII-dependent fibrinolysis in patients with stage II hypertension in combination with coronary heart disease was 3.54 times longer than the standard values (p<0,001), and the combination of hypertension III stage with CAD - 4.7 times longer than the norm (p< 0.001).
 Conclusions. Patients with hypertension stage II and III with concomitant coronary heart disease characterized by increased blood clotting activity in the background suppression of the anticoagulant and fibrinolytic components of hemostasis. The largest contribution to the formation of thrombophilic changes in patients of both treatment groups belongs to inhibition of fibrinolysis, which is more pronounced when hypertension stage III combined with coronary heart disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
